MONTREAL, Nov. 23, 2012 /CNW Telbec/ - Mr. Léon Gosselin, Chairman of
the Board of the Québec Consortium for Drug Discovery (CQDM), is
pleased to announce the appointment of Mrs. Diane Gosselin (no family
relationship) as President and Chief Executive Officer. Ms. Gosselin
will be replacing Mr. Max Fehlmann who announced today his resignation
from CQDM in order to take on the position of Chief Executive Officer
of NEOMED. However, the CQDM will continue to benefit from Mr.
Fehlmann's input as Strategic Advisor and member of the Board of
"CQDM is a proud contributor to the creation of NEOMED whose mission
complements our own," declared Diane Gosselin. While NEOMED will focus
on developing new drugs, CQDM remains dedicated to the development of
tools that enable drug development. "We will pursue our development
based on our unique business model where partners share the results of
their research projects. The results obtained to date clearly
demonstrate that our business model offers tangible results that
strongly impact the biopharmaceutical research sector," she added.
Mrs. Gosselin joined CQDM in September 2008 as Vice President, Research
and Business Development and was responsible for establishing all
funding programs and managing the Company's corporate development
activities. She boasts some twenty years of experience in research and
corporate financing, namely at Fonds de solidarité FTQ where she helped
several companies implement their drug development strategy. At PROCREA
BioSciences, she supervised the research team that created and
developed the first non-invasive diagnostic test for endometriosis.
Mrs. Gosselin holds a Ph.D. in microbiology and immunology from
Université de Montréal, as well as an Executive MBA from the Université
du Québec à Montréal and Université Paris-Dauphine.
The Québec Consortium for Drug Discovery (CQDM) is a hub for all
stakeholders in biopharmaceutical research. Its principal mission is to
fund joint research projects between the academic and private sectors.
An innovative Canadian initiative, the CQDM has a twofold goal: to
accelerate the drug discovery process and to develop safer and more
effective drugs. Project funding is made possible through contributions
from Pfizer Canada, AstraZeneca, Merck, Boehringer Ingelheim (Canada)
Ltd., GlaxoSmithKline Inc., Eli Lilly Canada Inc., the Business-Led
Networks of Centres of Excellence (BL-NCE), the Ministère de
l'Enseignement Supérieur et de la Science of Quebec and the Fonds de
recherche Québec - Santé (FRQS). For more information, visit www.cqdm.org.
For further information:
Cell.: 514 386-8211